MEA measurements using the Maestro™ MEA System

Measuring the extracellular field potential (EFP) of hiPSC-derived cardiomyocytes can be used to detect drug-induced effects on the electrophysiology of the cells. EFPs can be obtained noninvasively using microelectrode array (MEA) technology without the need for dyes. The multi-well Maestro™ MEA system (Axion BioSystems) enables EFP recordings in various multi-well plates.

User guide

hiPSC-derived cardiomyocytes optimized for use on the Maestro™ MEA System

We offer human iPSC-derived cardiomyocytes optimized for use in combination with the Maestro™ MEA System. Combining these technologies enables detailed electrophysiological detection of potential cardioactive and proarrhythmic effects of test compounds in 48- and 96-well plate formats.

This combination provides a highly relevant in vitro assay platform to study the cardiac safety or efficacy profile of compounds during drug development.

You can find our recommendations on how to combine our cardiomyocytes with the Maestro™ MEA system on 48- and 96-well plate formats for electrophysiology measurements in the following User Guides:

User Guide:


Cardiac safety assessment using hiPSC-derived cardiomyocytes in combination with the Maestro™ MEA system

Case studies were performed to assess the effects of cardioactive compounds on the electrophysiology of Pluricyte® Cardiomyocytes using the Maestro™ MEA system. Pluricyte® Cardiomyocytes show the expected pharmacological responses to reference compounds in a reproducible manner.

Download the complete application note here: